Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $91,960.00 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00. Following the transaction, the executive vice president now owns 116,071 shares of the company's stock, valued at approximately $5,336,944.58. This represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $48.06, for a total transaction of $96,120.00.
• On Tuesday, January 21st, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $45.92, for a total transaction of $91,840.00.
• On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00.
• On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $50.64, for a total transaction of $369,672.00.
• On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $50.16, for a total transaction of $366,168.00.

Cytokinetics Price Performance

CYTK traded down $0.86 during trading on Friday, hitting $50.26. 2,168,937 shares of the stock traded hands, compared to its average volume of 1,607,616. Cytokinetics, Incorporated has a twelve month low of $40.53 and a twelve month high of $81.36. The company has a market cap of $5.93 billion, a price-to-earnings ratio of -9.34 and a beta of 0.83. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The business has a 50 day moving average price of $47.26 and a 200 day moving average price of $51.55.

Analyst Upgrades and Downgrades

CYTK has been the subject of several recent analyst reports. Morgan Stanley upgraded shares of Cytokinetics from an "equal weight" rating to an "overweight" rating and cut their target price for the company from $70.00 to $67.00 in a research note on Thursday, February 13th. Evercore ISI upgraded shares of Cytokinetics to a "strong-buy" rating in a research note on Friday, February 7th. JMP Securities reiterated a "market outperform" rating and issued a $78.00 target price on shares of Cytokinetics in a research note on Friday, February 7th. Citigroup assumed coverage on shares of Cytokinetics in a research note on Friday, February 7th. They issued a "buy" rating and a $86.00 target price for the company. Finally, Mizuho increased their price target on shares of Cytokinetics from $99.00 to $103.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $82.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp raised its position in Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 374 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Cytokinetics during the fourth quarter worth $29,000. Blue Trust Inc. grew its stake in shares of Cytokinetics by 225.9% during the third quarter. Blue Trust Inc. now owns 981 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 680 shares during the last quarter. AlphaQuest LLC grew its stake in shares of Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 1,135 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Cytokinetics during the third quarter worth $54,000.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.